Invited Commentary

Evinacumab – The new kid on the block. Is it important for cardiovascular prevention?

1. What are angiopoietin-like proteins and what role do they play?

Angiopoietin-like proteins (ANGPTL) include the compounds ANGPTL1 through ANGPTL8 and belong to the vascular endothelial growth factor (VEGF) family [1–3]. ANGPTL3, ANGPTL4, and ANGPTL8 play an important role in terms of lipid metabolism. These proteins regulate the metabolism of triglyceride-rich lipoproteins (TRL) [4]. The main source of ANGPTL3 is liver, ANGPTL4 is from liver, adipose tissue, skeletal muscle, gut, heart and brain, and ANGPTL8 is from liver and adipose tissue. These proteins form a ANGPTL3-4-8 system that controls the availability of triglycerides depending on nutritional status, temperature, and physical activity [1–3,5].

Within white adipose tissue, lipoprotein lipase (LPL) activity is reduced by ANGPTL4 during fasting. In the heart, skeletal muscle, and brown adipose tissue, the activity of LPL after a meal is reduced by ANGPTL3 and ANGPTL8 (after a meal, the expression of ANGPTL8 is particularly increased, while the expression of ANGPTL3 is not dependent on the nutritional status) forming a heterodimer (ANGPTL8 is an activator of ANGPTL3). Thus, the ANGPTL3-4-8 system plays an important role in regulating triglyceride metabolism [1–3,5].

Fig. 1 summarizes the role of the ANGPTL3-4-8 system in the metabolism of triglyceride-rich lipoproteins.

2. Why is ANGPTL a promising drug target?

Dewey et al. reported that persons carrying the loss of function mutation of the Angptl3 gene have decreased serum low density lipoprotein (LDL) and triglyceride concentrations, which translated into a 41% predicted reduction in the risk of coronary artery disease (aOR = 0.59; 95% CI: 0.41–0.85, p = 0.004) [6].

Considering the important role of ANGPTL3 in lipid metabolism and the beneficial cardiovascular effects of inhibiting this protein, industry has developed a drug that is a human anti-ANGPTL3 monoclonal antibody – evinacumab (RENG1500).

3. What is evinacumab?

Evinacumab (trade name Evkeeza® by Regeneron Pharmaceuticals) is a humanized IgG4 anti-ANGPTL3 monoclonal antibody that was registered earlier this year with the U.S. Food & Drug Administration (FDA) for the treatment of homozygous familial hypercholesterolaemia (HoHF) [7]. The European Medicines Agency recently approved Evinacumab for the treatment of HoHF [8].

4. How does evinacumab work?

Evinacumab reduces its activity by forming an immune complex with ANGPTL3. Evinacumab lowers LDL-cholesterol predominantly by increasing apoB-containing lipoprotein clearance from the circulation [9].

5. Evinacumab in the treatment of lipid disorders - what are the results?

In a double-blind, placebo-controlled phase III study, Raal et al. assessed the therapeutic efficacy of evinacumab in 65 patients with HoHF. The subjects were administered evinacumab intravenously at a dose of 15 mg/kg every 4 weeks or placebo. The mean baseline plasma LDL concentration was 255 mg/dl despite intensive lipid lowering treatment. After 24 weeks, a significant improvement in lipid parameters was demonstrated (Fig. 2) [10]. Treatment with evinacumab is generally well tolerated and safe [11]. The results of clinical trials also indicate the beneficial effects of evinacumab in the treatment of resistant hypercholesterolaemia, heterozygous familial hypercholesterolaemia, and severe hypertriglyceridaemia [12–14]. Current studies with evinacumab are summarized in Table 1.

6. Conclusions and critical questions

The future of evinacumab seems a little different than that of other drugs used to treat severe hypercholesterolaemia, such as PCSK9 inhibitors (alirocumab, evolocumab) or PCSK9 small interfering RNA particles (inclisiran). The latter two do not address hypertriglyceridaemia. Thus, evinacumab could be the drug of choice, together with a statin, to treat mixed hyperlipidemia in very high cardiovascular risk patients. It could be the drug of choice for some patients in cardiovascular prevention, especially those with metabolic syndrome, diabetes, and hypertension occurring jointly. It might be helpful for some patients with atherogenic dyslipidemia. New clinical trials, however, are needed for broadening our experience with evinacumab in conjunction with ezetimibe, bempedoic acid, or even with PCSK9 inhibitors.

The critical questions for this drug are the following:

1. Will evinacumab be a better choice than PCSK9 blockade?
2. Will it change the way we treat hypertriglyceridaemia?
3. What will be optimal algorithm for introducing this drug within the family of old and new hypolipemic drugs?

https://doi.org/10.1016/j.ijcrp.2021.200107

Available online 8 September 2021
2772-4875/© 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Declaration of competing interest

None declared.

References

[1] S. Surma, M. Romaniczuk, K.J. Filipiak, Evinacumab - a new drug in the treatment of homozygous familial hypercholesterolemia, Integr. Canc. Sci. Therapeut. (2021), https://doi.org/10.15761/ICST.1000035.
[2] S. Surma, M. Romaniczuk, K.J. Filipiak, Angiopoietin-like proteins inhibitors: new horizons in the treatment of atherogenic dyslipidemia and familial hypercholesterolemia, Cardiol. J. (2021), https://doi.org/10.5603/CJ.a2021.0006.
[3] S. Surma, M. Romaniczuk, K.J. Filipiak, Evinacumab — an ANGPTL3 inhibitor; a new drug in the treatment of lipid disorders. Review on the literature and clinical studies, Folia Cardiol. 16 (2021) 30–39, https://doi.org/10.5603/FC.2021.0005.
[4] S. Kersten, New insights into angiopoietin-like proteins in lipid metabolism and cardiovascular disease risk, Curr. Opin. Lipidol. 30 (2019) 205–211, https://doi.org/10.1097/MOL.0000000000000600.
[5] R. Zhang, The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking, Open Biol. 6 (2016), 150272, https://doi.org/10.1098/rsob.150272.
[6] F. Dewey, V. Gusarova, R. Dunbar, et al., Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease, N. Engl. J. Med. 377 (2017) 211–221, https://doi.org/10.1056/NEJMoa1612790.
[7] https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2021. (Accessed 31 July 2021).
[8] https://www.ema.europa.eu/en/medicines/human/EPAR/evkeeza. (Accessed 31 July 2021).
[9] L.F. Reeskamp, J.S. Millar, L. Wu, et al., ANGPTL3 inhibition with evinacumab results in faster clearance of IDL and LDL apoB in patients with homozygous familial hypercholesterolemia-brief report, Arterioscler. Thromb. Vasc. Biol. 41 (2021) 1753–1759, https://doi.org/10.1161/ATVBAHA.120.315204.
[10] F. Raal, R. Rosenson, L. Reeskamp, et al., Evinacumab for homozygous familial hypercholesterolemia, N. Engl. J. Med. 383 (2020) 711–720, https://doi.org/10.1056/NEJMoa2004215.

[11] M. Harada-Shiba, C. Ali, D.A. Gipe, et al., A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects, Atherosclerosis 314 (2020) 33–40, https://doi.org/10.1016/j.atherosclerosis.2020.10.013.

[12] R. Rosenson, L. Burgess, C. Ebenbichler, et al., Evinacumab in patients with refractory hypercholesterolemia, N. Engl. J. Med. 383 (2020) 2307–2319, https://doi.org/10.1056/NEJMoa2031049.

[13] Z. Ahmad, P. Banerjee, S. Hamon, et al., Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia, Circulation 140 (2019) 470–486, https://doi.org/10.1161/CIRCULATIONAHA.118.039107.

[14] R. Rosenson, D. Gaudet, C. Ballantyne, et al., A phase 2 trial of the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia, in: American College of Cardiology’s 70th Annual Scientific Session & Expo; May 15 – 17, 2021.